1. Patients must have recurrent or persistent endometrial adenocarcarcinoma not amenable to management with surgery, radiation or higher priority or standard chemotherapy
2. Must have a GOG performance status of 0-2
3. Must have adequate or better bone marrow, kidney, and liver function
4. Must have adequate sensory or motor neuropathy ≤ grade 1
5. Cannot have an active infection requiring antibiotics
6. Cannot have had prior biologic or immunologic agents directed at the malignant tumor within 3 weeks of study
7. Can have one prior non-cytotoxic (biologic or cytostatic) regimen for management of recurrent or persistent disease (includes, but is not limited to monoclonal antibodies, cytokines, or small-molecule inhibitors of signal transduction). Cannot have had more than 1 prior cytotoxic chemotherapy regimen (either single or combination drug therapy)
8. Must not have received prior ixabepilone but can have received prior paclitaxel or docetaxel

1. Patients must have advanced (stage III or IV), persistent or recurrent uterine carcinosarcoma (mixed mesodermal tumor [MMT] with documented disease progression
2. Must have disease that can be measured with at least one lesion > 20 mm when measured by conventional techniques, or > 10 mm when measured by spiral CT; must have at least one “target lesion” as defined by RECIST (tumors within a previously irradiated field will be designated as “non-target” lesions)
3. Must have recovered from effects of recent surgery, radiotherapy or other therapy
4. Should be free of active infection requiring antibiotics and have no lung disease requiring oxygen
5. Must have discontinued any hormonal therapy directed at the malignant tumor at least one week prior to registration
6. Must have adequate bone marrow function, kidney, liver, and neurological function
7. Must be 18 years of age or older.

1. Must have histologically confirmed ovarian epithelial or primary peritoneal cancer with recurrent or persistent disease, and at least 1 uni-dimensionally target lesion that measures at least 20 mm by conventional techniques or at least 10 mm by spiral CT scan
2. Must be 18 years of age or older
3. Must have adequate absolute bone marrow, liver and kidney function
4. Must not have any serious cardiac disease, history of myocardial infarction, and uncontrolled congestive heart failure, or pulmonary disease requiring oxygen
5. Cannot have active infections requiring antibiotics 
6. Cannot have prior radiotherapy to more than 25% of marrow-bearing areas

1. Patients must have a confirmed diagnosis of recurrent or persistent endometrial carcinoma.
2. Patients must have measurable disease.
3. Patents must have at least one “target lesion” to assess response on this study as defined by RECIST.
4. Patients must have recovered from the effects of recent surgery, radiotherapy or chemotherapy.
5. Patients must not be eligible for a higher priority GOG study.
6. Patients who have had one prior regimen must have a GOG performance status of 0,1, or 2.
7. Patients must have had one prior chemotherapeutic regimen for the management of endometrial carcinoma.
8. Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for the management of their disease.
9. Patients may not have received any non-cytotoxic chemotherapy for the management of their disease.
10. Patients must have adequate bone marrow, kidney, liver and neurologic function.

1. Patients must have a confirmed diagnosis of recurrent, persistent or metastatic endometrial cancer that is not curable with either surgery or radiation therapy.
2. Patients must have at least one “target lesion” to be used to assess response on this study as defined by RECIST.
3. Patients must have a GOG performance status of 0 or 1.
4. Patients must have adequate bone marrow, kidney, and liver function.
5. Patients may have received prior surgery, radiation therapy or hormonal treatment.

1. Patients must have a confirmed diagnosis of recurrent or persistent endometrial carcinoma.
2. Patients must have measurable disease.
3. Patients must have one “target lesion” to be used to assess response on this protocol as defined by RECIST. 
4. Patients must not be eligible for a higher priority GOG protocol.
5. Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2.
6. Patients must have recovered from the effects of recent surgery, radiotherapy, or chemotherapy.
7. Patients must have had one prior chemotherapeutic regimen for the management of endometrial carcinoma.
8. Patients are allowed to receive, but are not required to receive, one additional cytotoxic regiment for the management of their disease.
9. Patient must not have received any non-cytotoxic chemotherapy for management of recurrent or persistent disease.
10. Patients must have adequate bone marrow, kidney, liver and neurologic function.

1. Patients must have a confirmed diagnosis of epithelial ovarian cancer, tubal cancer, or primary peritoneal cancer and have received only one first-line chemotherapy regimen (platinum/taxane based).
2. Patients must be clinical and radiologically without evidence of measurable and non-measurable disease.
3. Patient’s CA-125 must be normal prior to or during first -line chemotherapy.
4. Patients must not be eligible for higher priority GOG protocol.
5. Patients must have a GOG performance status of 0-1.
6. Patients must have recovered from effects of recent surgery, chemotherapy, and/or radiotherapy and be free of significant infection.
7. Patients must have adequate bone marrow, kidney, liver and neurologic function.

1. Patients must have a confirmed diagnosis of primary peritoneal carcinoma or epithelial ovarian carcinoma, Stage III or IV, with either optimal or suboptimal residual disease following initial surgery.
2. Patients must have completed treatment within the past 6 weeks with at least 5 cycles and not more than 6 cycles of carboplatin (IV or IP) and paclitaxel or docetaxel-based combination chemotherapy and have no symptoms suggestive of persistent cancer.
3. Patients must have adequate bone marrow, kidney, liver and neurologic function.
4. Patients must have a GOG performance status of 0, 1, or 2.

1. Patients must have a confirmed diagnosis of uterine cancer that is persistent or recurrent with documented disease progression after appropriate local therapy.
2. All patients must have measurable disease.
3. Patients must have at least one “target lesion” to be used to assess response on this study as defined by RECIST.
4. Patients must not be eligible for a higher priority GOG protocol, if one exists.
5. Patients who have received one prior regimen must have a GOG performance status of 0, 1, or 2.
6. Patients must have recovered from the effects of recent surgery, radiotherapy, or chemotherapy and be free of active infection requiring antibiotics.
7. Patients must have had one prior chemotherapeutic regimen for the management of carcinosarcoma.
8. Patients are allowed to receive, but not required to receive, once additional cytotoxic regimen for the management of recurrent or persistent disease according to study parameters.
9. Patients must not have received any non-cytotoxic chemotherapy for management of recurrent or persistent disease.
10. Patients must have adequate bone marrow, liver, kidney, and neurologic function.

1. Patients with recurrent epithelial ovarian cancer, primary peritoneal or fallopian tube cancer that is considered platinum sensitive will be eligible for this trial.
2. Patients must have measurable disease that is not in a previously irradiated field.
3. Patients must have received prior therapy with a platinum-based regimen before study enrollments but must not have had more than 2 chemotherapy regimens, and must be platinum sensitive. Prior hormonal therapy is allowed.
4. Patients must have a life expectancy of greater than 12 weeks.
5. Patients must have normal liver, kidney and bone marrow function.

1. Patients must have a histologic diagnosis of epithelial ovarian, primary peritoneal or fallopian tube carcinoma, Stage III or IV, with either optimal (< 1 cm residual disease) or suboptimal residual disease following initial surgery. Must be no more than 12 weeks postoperatively.
2. Must have a GOG performance status of 0-2.
3. Patients must have adequate bone marrow, kidney, liver, and neurologic function.
4. Patients must not have received any prior treatment other than surgery.
5. Must not have an active infection or active bleeding.
6. Patients must not have unstable angina or have had a myocardial infarction in the past 6 months. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status has been stable for 6 months.
7. Patients with synchronous primary endometrial cancer, or past history of endometrial cancer are not eligible unless 1) the stage is not greater than IB, 2) the cancer has less than a 3 mm invasion without vascular or lymphatic invasion, or 3) the cancer is not of a poorly differentiated subtype.
8. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer and localized breast cancer. 

1. Patients must have advanced, recurrent or persistent endometrial carcinoma which is refractory to curative therapy. Disease must demonstrate HER2/neu gene amplification by FISH assay.
2. Must have a GOG performance status of 0-2.
3. Patients must have adequate bone marrow, kidney, liver, heart and lung function.
4. Must have recovered from effects of recent surgery, radiotherapy or chemotherapy.
5. Patients must have measurable disease.
6. Must be free of active infection.
7. Patients must not have unstable angina or have had a myocardial infarction in the past 6 months. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status has been stable for 6 months.
8. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer.
9. Must not have an unstable medical condition or require supplemental oxygen. 

1. Patients must have recurrent or persistent ovarian or primary peritoneal cancer. Must have had one prior platinum-based chemotherapy regimen containing carboplatin, cisplatin or other organoplatinum compound. 
2. Must have measurable disease.
3. Must have a GOG performance status of 0-2.
4. Patients must have adequate bone marrow, kidney, liver, and neurologic function.
5. Must have recovered from effects of recent surgery, radiotherapy or chemotherapy.
6. Patients must not have an active infection.
7. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer.

1. Patients must have recurrent carcinoma of the cervix with documented disease progression. Must have had one prior chemotherapy regimen for management of persistent or recurrent carcinoma of the cervix.
2. Must have measurable disease.
3. Must have a GOG performance status of 0-2.
4. Patients must have adequate bone marrow, kidney, liver, and neurologic function.
5. Must have recovered from effects of recent surgery, radiotherapy or chemotherapy.
6. Patients must not have an active infection.
7. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer.

1. Patients must have diagnosis of primary peritoneal, fallopian tube or ovarian carcinoma, Stage III or IV with either optimal (< 1 cm residual disease) or suboptimal residual disease following initial surgery. Patients must be entered on study no more than 12 weeks post operatively. Patients with carcinosarcoma are eligible.
2. Must not have received prior radiotherapy or chemotherapy.
3. Must have adequate bone marrow, kidney and liver function.
4. Must have a GOG performance status 0-2.
5. Patients must not have a severe infection, active bleeding or acute hepatitis.
6. Patients must not have unstable angina or have had a myocardial infarction in the past 6 months. Patients with evidence of cardiac conduction abnormalities are eligible if their cardiac status has been stable for 6 months.
7. Patients with synchronous primary endometrial cancer, or past history of endometrial cancer are not eligible unless 1) the stage is not greater than IB, 2) the cancer has less than a 3 mm invasion without vascular or lymphatic invasion, or 3) the cancer is not of a poorly differentiated subtype.
8. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer and localized breast cancer. 
9. Patients must not have a history of an allergic reaction to polysorbate 80.

1. Patients must have recurrent or persistent endometrial carcinoma which is refractory to curative therapy or established treatments. Must have had one prior chemotherapy regimen.
2. Must have measurable disease.
3. Must have a GOG performance status of 0-2.
4. Patients must have adequate bone marrow, kidney, liver, and neurologic function.
5. Must have recovered from effects of recent surgery, radiotherapy or chemotherapy.
6. Patients must not have an active infection requiring antibiotics.
7. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer.

1. Patients must have primary, previously untreated histologically confirmed invasive carcinoma of the uterine cervix. Clinical stages IB2, IIA, IIB, IIIA, IIIB and IVA with negative para-aortic lymph nodes or biopsy negative para-aortic nodes if CT scan is suspicious for adenopathy. Must be entered within 8 weeks of diagnosis
2. Must have adequate bone marrow, kidney and liver function. 
3. Patients must not have renal abnormalities such as pelvic kidney, horseshoe kidney or renal transplantation which would require modification of the radiation fields.
4. Must have a GOG performance status of 0-2.
5. Patients must not have a severe infection.
6. Must not have had a history of other invasive malignancies within the last 5 years with the exception of non-melanoma skin cancer.

1. Patients must have primary Stage III or IV or recurrent endometrial carcinoma whose potential for cure by radiation therapy or surgery alone or in combination is very poor. May not have received prior chemotherapy. At least 4 weeks should have elapsed since completion of radiation therapy.
2. Must have measurable disease.
3. Must have adequate bone marrow, liver and heart function.
4. Must have a GOG performance status 0-2.
5. Must not have a concomitant malignancy with the exception of non-melanoma skin cancer. Patients with a prior malignancy who have been disease free for < 5 years or who received prior chemotherapy for that malignancy are not eligible.
6. Patients must not have a concomitant medical illness such as serious uncontrolled infection, uncontrolled angina or serious peripheral neuropathy. Patients with a third degree or complete heart block are not eligible unless a pacemaker is in place.
7. Must not be sensitive to E. Coli-derived drug preparations.

1. Patients must have recurrent or persistent ovarian or primary peritoneal carcinomas. Must have had one prior platinum-based chemotherapy regimen containing carboplatin, cisplatin or other organoplatinum compound. Must be considered platinum-sensitive according to standard GOG criteria.
2. Must have measurable disease.
3. Patients who have received one prior therapy regimen must have a GOG performance status of 0-2. Patients who have received two prior therapy regimens must have a GOG performance status 0-1.
4. Must have recovered from the effects of recent surgery, radiotherapy or chemotherapy.
5. Must be free of active infection requiring antibiotics.
6. Patients must have adequate bone marrow, kidney, liver and neurologic function.
7. Must not have received a prior bone marrow or stem cell transplant.
8. Must not have a history of retinopathy and/or macular degeneration.
9. Patients must not have a history of congestive heart failure requiring medication or uncontrolled hypertension within the past 6 months.
10. Patients with a history of other invasive malignancies with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years.

1. Patients must have histologically proven stage IVB, recurrent or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.
2. Must have measurabl disease.
3. Must have adequate bone marrow, kidney and liver function.
4. Must have a GOG performance status 0-1.
5. Patients must have recovered from the effects of surgery, radiation therapy or chemoradiotherapy. At least 6 weeks must have elapsed from the last administration of chemoradiotherapy and at least 3 weeks must have elapsed from the administration of radiation therapy alone.
6. Must be free of clinically significant infection.
7. Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage are not eligible.
8. Patients may not have received prior treatment with chemotherapy alone.
9. Must not have craniospinal metastases.
10. Patients with a history of other invasive malignancies with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years.

1. Age greater than or equal to 30
2. No prior history of ovarian cancer, including low malignant potential cancers (LMP, or primary papillary serous carcinoma of the peritoneum.
3. Ovary status: To be eligible for the RRSO arm of this study, subjects must have at least one intact ovary, to be eligible for the screening arm of this study which targets primary ovarian cancer as the endpoint, subjects must have at least one intact ovary; to be eligible for the screening arm of this study which targets primary peritoneal cancer as the endpoint, both ovaries and fallopian tubes must have been removed. This option is available only to women who have undergone removal of their ovary/ovaries while actively participating in GOG-0199.
4. Subjects must have satisfied at least 1 of the following additional criteria:
   a. The family of the subject has a documented deleterious BRCA1 or BRCA2 mutation – either: (1) the subject herself has tested positive for a BRCA1 or BRCA2 mutation or (2) the subject has a first-or second-degree relative with a BRCA1 or BRCA2 mutation; or 
   b. the family contains at least two ovarian or breast cancers among the subject or first or second degree relatives of the subject within the same lineage. This condition is satisfied by multiple primary cancers in the same person. Where breast cancer is required to meet this criterion, at lest one breast cancer must be pre-menopausal (age at diagnosis less than or equal to 50 if age at menopause is unknown); or 
   c. the subject is of Ashkenazi Jewish ethnicity with one first degree or two second degree relatives with breast or ovarian cancer or subject is of Ashkenazi ancestry and has had breast cancer. 
5. Subjects with first or second degree relative has a deleterious BRCA1/2 mutation, and the subject has tested NEGATIVE for the exact same mutation, are ineligible. 
6. Subjects who are currently pregnant or planning pregnancy during the study are ineligible.
7. Subjects who are participating in another ovarian cancer early detection trial.
8. Subjects with current untreated malignancy.
9. Subjects with adjuvant radiation therapy or chemotherapy within the past 3 months.
10. Subjects who have been treated for prior metastatic malignant disease within the past 5 years.
11. Subjects who have undergone intraperitoneal surgery within the prior 3 months. 
12. Subjects who have had both ovaries removed prior to study entry

1. Patients must have carcinoma of the uterine cervix with evidence for positive 
   para-aortic or high common iliac lymph nodes.
2. Patients will squamous cell, adenocarcinoma, and adenosquamous carcinoma are 
   eligible.
3. Patients must have no evidence of metastatic disease outside of the pelvis (except to the para-aortic nodes).
4. Patients must have adequate bone marrow, hepatic and renal function.
5. Patients must no have received prior systemic chemotherapy; no pelvic radiation therapy is permitted other than transvaginal irradiation to control bleeding.

1. Histologic diagnosis of ovarian cancer which is a completely resected stage II, IC or IA or IB
2. No prior treatment except surgery
3. Adequate bone marrow, renal and liver function
4. GOG performance status 0-3
5. Must not have any major systemic illness expected to affect survival
6. Must be entered within 6 weeks of staging surgery

GOG 9703: A Phase I Study of Paclitaxel, Carboplatin and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal and Tubal Carcinoma

1. Untreated patients with a histologic diagnosis of ovarian , peritoneal or tubal carcinoma
2. Adequate bone marrow, renal, heart and liver function
3. GOG performance status 0-2
4. No active infection or serious concurrent medical disease

GOG 174: A Randomized Phase III Trial of Weekly Parenteral Methotrexate versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia

1. Untreated histologically confirmed low risk gestational trophoblastic neoplasia
2. WHO score 0 to 4
3. Adequate bone marrow, renal and liver function
4. GOG performance 0-2
5. No prior chemotherapy
6. No evidence of metastatic disease

1. Stage III or IV endometrial cancer
2. Must have had a hysterectomy and bilateral salpingo-oophorectomy and be enrolled within 8 weeks of surgery. Tumor must be maximally cytoreduced to 2 cm or less
3. Performance status 0-2
4. Adequate hematologic, heart, liver and kidney function
5. No prior chemotherapy, pelvic or abdominal radiation therapy
6. Must not have metastatic disease involving the lung or liver parenchyma, or positive inguinal or supraclavicular lymph nodes, malignant pleural effusion, or any other evidence of metastases outside the abdominopelvic area

Nancy Fusco, RN 216-844-1661

Diagnosed with histologically confirmed ovarian stromal tumor [granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord stromal tumor, sex cord tumor with annular tubules].

Patients may have either previously untreated disease, which was diagnosed within eight weeks prior to entry on study, or recurrent stromal tumor having received no more than one prior chemotherapy regimen.

3. Patients must have a GOG performance grade of 0, 1, or 2.